Vanguard Global Advisers’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
Other funds holding PCRX
Vanguard Global Advisers's PCRX Position: Q3 2026 in Review
Vanguard Global Advisers increased its Pacira BioSciences (PCRX) stake by 14% in Q3 2026, buying an estimated $292K and bringing the position to 94,227 shares worth $2.36M. The position accounts for ﹤0.01% of the portfolio, ranked #1138.
Vanguard Global Advisers first reported a position in PCRX in Q1 2026 and has held it in 3 quarters since. 257 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.
- Vanguard Global Advisers held 94,227 shares of Pacira BioSciences worth $2.36M as of Q3 2026.
- Vanguard Global Advisers bought 11,515 Pacira BioSciences shares in Q3 2026, an estimated $292K.
- Pacira BioSciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1138 holding.
- Vanguard Global Advisers first reported a position in Pacira BioSciences in Q1 2026 and has held it in 3 quarters since.
- 257 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.